Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Numerous studies have established a causal link between aberrant mammalian target of rapamycin (mTOR) activation and tumorigenesis, indicating that mTOR inhibition may have therapeutic potential. In this study, we show that rapamycin and its analogs activate the MAPK pathway in human cancer, in what...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of clinical investigation 2008-09, Vol.118 (9), p.3065-3074
Hauptverfasser:	Carracedo, Arkaitz, Ma, Li, Teruya-Feldstein, Julie, Rojo, Federico, Salmena, Leonardo, Alimonti, Andrea, Egia, Ainara, Sasaki, Atsuo T, Thomas, George, Kozma, Sara C, Papa, Antonella, Nardella, Caterina, Cantley, Lewis C, Baselga, Jose, Pandolfi, Pier Paolo
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Biomedical research Biopsy Cancer Cell growth Cell Line, Tumor Cell proliferation Clinical trials Control Dosage and administration Drug dosages Enzyme Activation Enzyme Inhibitors - pharmacology Everolimus Feedback Feedback, Physiological Gene Expression Regulation, Neoplastic Genetic aspects Growth factors Humans Immunosuppressive Agents - pharmacology Kinases MAP Kinase Signaling System Mechanistic Target of Rapamycin Complex 1 Metastasis Mice Multiprotein Complexes Neoplasms - enzymology Neoplasms - metabolism Patients Phosphorylation Prostate cancer Proteins Rapamycin Risk factors Sirolimus - analogs & derivatives Sirolimus - pharmacology TOR Serine-Threonine Kinases Transcription Factors - antagonists & inhibitors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!